Onsdag 18 November | 10:32:58 Europe / Stockholm
Est. tid*
2027-05-19 07:00 Kvartalsrapport 2027-Q1
2027-02-16 07:00 Bokslutskommuniké 2026
2026-11-18 07:00 Kvartalsrapport 2026-Q3
2026-08-21 - Kvartalsrapport 2026-Q2
2026-05-29 - X-dag ordinarie utdelning NEOLA 0.00 SEK
2026-05-28 - Årsstämma
2026-05-19 - Kvartalsrapport 2026-Q1
2026-02-12 - Bokslutskommuniké 2025
2025-11-05 - Kvartalsrapport 2025-Q3
2025-08-22 - Kvartalsrapport 2025-Q2
2025-05-22 - X-dag ordinarie utdelning NEOLA 0.00 SEK
2025-05-21 - Årsstämma
2025-05-21 - Kvartalsrapport 2025-Q1
2025-02-12 - Bokslutskommuniké 2024
2024-11-06 - Kvartalsrapport 2024-Q3
2024-08-15 - Kvartalsrapport 2024-Q2
2024-05-23 - X-dag ordinarie utdelning NEOLA 0.00 SEK
2024-05-22 - Årsstämma
2024-05-22 - Kvartalsrapport 2024-Q1
2024-02-14 - Bokslutskommuniké 2023
2023-12-29 - Extra Bolagsstämma 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-08-15 - Kvartalsrapport 2023-Q2
2023-05-19 - X-dag ordinarie utdelning NEOLA 0.00 SEK
2023-05-17 - Årsstämma
2023-05-17 - Kvartalsrapport 2023-Q1
2023-02-14 - Bokslutskommuniké 2022
2022-11-10 - Kvartalsrapport 2022-Q3
2022-09-27 - Extra Bolagsstämma 2022
2022-08-16 - Kvartalsrapport 2022-Q2
2022-05-20 - X-dag ordinarie utdelning NEOLA 0.00 SEK
2022-05-19 - Årsstämma
2022-05-19 - Kvartalsrapport 2022-Q1
2022-02-15 - Bokslutskommuniké 2021
2021-11-09 - Kvartalsrapport 2021-Q3
2021-09-14 - Extra Bolagsstämma 2021
2021-08-17 - Kvartalsrapport 2021-Q2
2021-05-21 - X-dag ordinarie utdelning NEOLA 0.00 SEK
2021-05-20 - Årsstämma
2021-05-20 - Kvartalsrapport 2021-Q1
2021-02-16 - Bokslutskommuniké 2020
2020-11-11 - Kvartalsrapport 2020-Q3
LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Neola Medical är verksamt inom medicinteknik. Bolaget är inriktade mot neonatalvården där de utvecklar medicinteknisk utrustning. Exempel på produkter som bolaget tillhandahåller till sjukvården inkluderar teknisk övervakning och uppföljning av lungkapaciteten hos tidigt födda spädbarn. Utöver huvudprodukten erbjuds kringprodukter och engångsartiklar. Störst verksamhet återfinns inom den nordiska marknaden. Neola Medical grundades 2016 och har huvudkontor i Sverige.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Neola Medical Q3 Report 2026 – FDA Breakthrough Device Designation strengthens U.S. regulatory pathway

2026-11-18 07:55:00

During the third quarter, Neola Medical reached a major regulatory milestone as the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to Neola®. The designation recognizes the device's potential to address an important unmet need in neonatal intensive care and provides opportunities for prioritized interaction with the FDA. The Company also strengthened its intellectual property portfolio with a U.S. design patent and continued preclinical validation focused on pneumothorax detection.

Summary of the period July-September 2026

  • Operating income: SEK 0k (0)
  • Operating result: SEK –3 332k (-2 833)
  • Cash flow for the period: SEK 17 051k (-4 390)
  • Result per share: -0,03 SEK (-0,04)

CEO comments

FDA Breakthrough Device Designation marks a defining milestone
The third quarter marked a significant milestone for Neola Medical. In September, the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to Neola®, recognizing its potential to address an important unmet need in neonatal intensive care. The designation is a major step in our U.S. regulatory journey and reinforces our strategy to focus on continuous, non-invasive monitoring to support timely detection of pneumothorax (lung collapse) in preterm born babies.

A stronger regulatory pathway
Breakthrough Device Designation provides opportunities for more frequent, prioritized interaction with the FDA as we develop the evidence required for market authorization. While it does not constitute market approval, it creates a valuable framework for early alignment on clinical study design and regulatory expectations. Following the quarter, Neola® was enrolled in the FDA's Total Product Life Cycle Advisory Program (TAP) Pilot, which provides earlier and more frequent strategic engagement with the agency.

Focused development and clinical preparations
During the quarter, we advanced our preclinical validation program with a sharpened focus on pneumothorax detection, building on earlier encouraging findings in preclinical models that Neola® can detect changes associated with pneumothorax in several types of animals. Ongoing work is focused on strengthening the robustness of the detection approach and generating preclinical data to inform the next development steps.

In parallel, we continued planning for the U.S. clinical program, engaging neonatologists, regulatory advisors and contract research organizations. Our aim is to establish an evidence-generation strategy that meets FDA requirements while remaining proportionate to the clinical need and supporting future adoption by neonatal intensive care units.

Investing in critical milestones
Our increased cash burn reflects a deliberate acceleration of targeted preclinical, regulatory and clinical planning activities, supported by specialist external expertise. These investments have been directed toward achieving key milestones and reducing uncertainty in the development pathway and the commercial opportunities. We remain disciplined in allocating capital to activities that can advance regulatory alignment, strengthen clinical evidence and support long-term value creation.

Priorities ahead
Our next priorities are to further validate pneumothorax detection, align with the FDA on an efficient clinical and regulatory strategy, and define the scope, timing and financing of the next development phase. The Breakthrough Device Designation strengthens Neola Medical's regulatory position and marks an important step toward the U.S. market. With a clearly defined clinical application and enhanced opportunities for FDA engagement, we are well positioned to advance our clinical and regulatory development. Our priority remains disciplined execution, capital efficiency and long-term value creation through progress toward market authorization and clinical adoption.

Hanna Sjöström, CEO

The full report is attached to this press release and available on Neola Medical's website, www.neolamedical.com

Lund, November 18, 2026
The Board